Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Formulary Guidelines Back In Spotlight With Essential Health Benefits Proposal

Executive Summary

HHS proposes to use USP’s drug classification system, created as a guideline for Medicare Part D formularies, to facilitate “review, analysis and comparison” of the breadth of drug coverage offered by individual and small group private insurance plans beginning in 2014.

Advertisement

Related Content

USP Draft Medicare Formulary Update Adds Nine Classes, Targeted Cancer Drugs
USP’s Draft Revisions To Medicare Formulary Guidelines Coming In September
HHS Essential Health Benefits Drug Coverage Provisions Unchanged In Final Rule
Payers Seek Greater Flexibility In HHS Formulary Standards For Health Plans
State Reluctance On Insurance Exchanges Means Continued Uncertainty On Drug Access Issues
State Bills Setting Specialty Tier Limits Await Health Reform Developments
How Often Should Part D's Model Formulary Be Revised? USP And CMS Disagree

Topics

Advertisement
UsernamePublicRestriction

Register

PS054946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel